Related Experiment Video
Updated: Jun 5, 2025
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.2K
Dual-Enhanced SERS Satellite Immuno-Nanocomplex for Multiple PSA-Mediated PHI Assay Toward Clinical Prostate Cancer
Dong Chen1,2, Yilin Ma1,3, Annan Yang1,3
1Institute for Safflower Industry Research, Key Laboratory of Xinjiang Phytomedicine Resource and Utilization (Ministry of Education), School of Pharmacy, Shihezi University, Shihezi, 832003, China.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|December 10, 2024
Summary
This study introduces a novel immunoassay for prostate cancer (PCa) screening by measuring multiple prostate specific antigens (PSA). The method enhances diagnostic accuracy, especially for ambiguous cases, improving early detection and monitoring.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Diagnostics
Background:
- Prostate specific antigen (PSA) is a key biomarker for prostate cancer (PCa) but lacks specificity.
- Existing PSA assays often focus on total PSA (tPSA) and free PSA (fPSA), limiting diagnostic accuracy, particularly in the
- diagnostic gray zone".
Purpose of the Study:
- To develop a highly specific and accurate diagnostic tool for prostate cancer (PCa) screening.
- To enhance the predictive accuracy of PCa diagnosis by assessing multiple PSA forms.
- To create a sensitive biosensor for early detection and monitoring of PCa.
Main Methods:
- Fabrication of a double-Surface-Enhanced Raman Spectroscopy (SERS) satellite immunoassay using gold-silver dealloyed intra-nanogap nanoflowers (Au-Ag DINF) and gold magnetic nanoparticles (AuMNPs).
- Simultaneous detection and quantification of multiple PSA forms: free PSA (fPSA), complexed PSA (cPSA), and [-2]proPSA (p2PSA).
- Development of a Prostate Health Index (PHI) assay incorporating multiple PSA measurements for improved PCa prediction.
Main Results:
- The developed SERS immunoassay demonstrated high sensitivity and specificity in distinguishing PCa patients from healthy individuals.
- The assay successfully monitored PCa patients before and after surgery.
- The multiple PSA-based PHI assay showed improved accuracy in screening suspicious cases within the tPSA "diagnostic gray zone".
Conclusions:
- The novel double-SERS satellite immunoassay offers a promising strategy for early prostate cancer (PCa) diagnosis and screening.
- The multi-PSA Prostate Health Index (PHI) assay significantly improves the specificity and predictive accuracy of PCa detection.
- This bioassay holds potential for comprehensive PCa management, including early diagnosis, screening, monitoring, and prognosis.
